Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular characterization of colorectal cancer-related peritoneal metastatic disease

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE183917 | GEO | 2022/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular characterization of colorectal cancer related peritoneal metastatic disease.

Project description:A significant proportion of colorectal cancer (CRC) patients develop peritoneal metastases (PM) in the course of their disease. PMs are associated with a poor quality of life, significant morbidity and dismal disease outcome. To improve care for this patient group, a better understanding of the molecular characteristics of CRC-PM is required. Here we present a comprehensive molecular characterization of a cohort of 52 patients. This reveals that CRC-PM represent a distinct CRC molecular subtype, CMS4, but can be further divided in three separate categories, each presenting with unique features. We uncover that the CMS4-associated structural protein Moesin plays a key role in peritoneal dissemination. Finally, we define specific evolutionary features of CRC-PM which indicate that polyclonal metastatic seeding underlies these lesions. Together our results suggest that CRC-PM should be perceived as a distinct disease entity.

| S-EPMC9352687 | biostudies-literature

Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

Project description:We present a comprehensive molecular characterization of a cohort of 52 patients with peritoneal metastasis

2022-06-01 | GSE183202 | GEO

Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

Project description:We present acomprehensive molecular characterization of a cohort of 5 patients with peritoneal metastasis

2022-06-30 | GSE183916 | GEO

Molecular characterization of colorectal cancer-related peritoneal metastatic disease

Project description:Molecular characterization of colorectal cancer-related peritoneal metastatic disease

| PRJNA762330 | ENA

Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

Project description:Molecular characterization of colorectal cancer-related peritoneal metastatic disease [RNA-seq]

| PRJNA759609 | ENA

Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

Project description:Molecular characterization of colorectal cancer related peritoneal metastatic disease [scRNA-seq]

| PRJNA762334 | ENA

Molecular Tools for Metastatic Colorectal Cancer Characterization

Project description:In our recent publication [1], we have explored at the molecular level the consequences of reovirus administration to patients with KRAS mutated colorectal cancer (CRC). This was the first reported study where transcriptome assay was performed on KRAS mutated CRC patients receiving reovirus (pelareorep) therapy. Using peripheral mononuclear cells as a tumor surrogate, we have identified several hundred genes that were significantly altered in a transcriptome assay of patients receiving pelareorep serving as their own controls (pre and post reovirus administration) and compared to untreated controls [2]. We focused primarily on 884 immune related genes and published the data for genes with significance probability of 0.001 (1 in thousand for a perfect random occurrence). Samples were collected at 48 hours, day 8 and day 15 post reovirus administration and compared for dynamic gene expression alterations over time. Using PBMC we also performed flow cytometry, cytokine ELISA, immunohistochemistry, and determination of the expression level of CRC specific microRNA miR-29a-3p. Our data supports the therapeutic competence of reovirus and identifies the four major ways by which it exerts its antitumor effects.

| S-EPMC7793569 | biostudies-literature

Omics profiling of 21 novel primary and metastatic colorectal cancer cell lines

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-02-29 | E-GEOD-67775 | biostudies-arrayexpress

Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-08-17 | GSE72970 | GEO

Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer.

Project description:BackgroundEarly onset colorectal cancer (EO CRC) is a heterogeneous colorectal cancer subtype with obvious hereditary tendencies and increasing incidence. We sought to determine the susceptibility genes and molecular characteristics of EO CRC.Methods330 EO metastatic CRC (mCRC) (≤55 years) and 110 average-onset (AO) mCRC patients (>55 years) were enrolled. Capture-based targeted sequencing was performed on tumor tissue and paired white blood cells using a sequencing panel of 520 genes. The association between molecular alterations and overall survival (OS) was analyzed.ResultsOf the 330 EO mCRC patients, 31 carried pathogenic or likely pathogenic germline mutations, with 16 of them diagnosed with lynch syndrome. Fifteen patients had germline mutations in non-mismatch repair genes, including four in MUTHY, three in RAD50, one in TP53, and eight in other genes. Twenty-nine genes were recurrently mutated in EO mCRC, including TP53, APC, KRAS, SMAD4, and BRCA2. The majority of genomic alterations were comparable between EO and AO mCRC. EO mCRC patients were more likely to have a high tumor mutation burden (p < 0.05). RNF43, RBM10, TSC, and BRAF V600E mutations were more commonly observed in EO mCRC, while APC, ASXL1, DNMT3B, and MET genes were more commonly altered in AO patients. At the pathway level, the WNT pathway was the only differentially mutated pathway between EO and AO mCRC (p < 0.0001). The wild-type WNT pathway (p = 0.0017) and mutated TGF-β pathway (p = 0.023) were associated with unfavorable OS in EO mCRC.ConclusionsApproximately one in 10 EO mCRC was associated with hereditary tumors. The spectrum of somatic alterations was largely comparable between EO and AO mCRC with several notable differences.

| S-EPMC7604404 | biostudies-literature